Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 BCMA CAR T-cell therapy in early-relapsed or primary refractory multiple myeloma
TCTR20260507012Phase 2Recruiting
- Sponsor
- Ramathibodi Foundation
- Start
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM), sponsored by Ramathibodi Foundation. Primary endpoint: Safety profile. Started Apr 2026; status: recruiting.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on TCTR20260507012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260507012.